Neothetics (NEOT) Narrows Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 8:01 AM EDTSAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq: NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results for the fourth quarter and year ended December 31, 2014.
2014 Key Corporate Highlights
On November 20, 2014, completed an initial public offering of 4,650,000 common shares on NASDAQ resulting in $65.1 million in gross proceeds, which exceeded the initial range of estimated proceeds. Completed private equity Series C and D rounds to raise approximately $14 million in gross proceeds to fund clinical development of LIPO-202. Conducted... More